PRMB vs PRAX
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
PRMB · Primo Brands$23.23 ▼ 0.26%
PRAX · Praxis Precision Medicines$300.43 ▼ 3.37%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- PRMB +58.8%
- PRAX +57.4%
Head to head
| Metric | PRMB | PRAX |
|---|---|---|
| Price | $23.23 | $300.43 |
| Change today | ▼ 0.26% | ▼ 3.37% |
| Market cap | $8.40B | $8.40B |
| Return, 3 months | +0.9% | -18.4% |
| Return, year to date | +44.3% | +1.9% |
| Return, 1 year | +57.8% | +76.9% |
| P/E (TTM) | 40.8 | – |
| P/B | 2.8 | 6.7 |
| P/E percentile vs own 5y | 85th | 3rd |
| Dividend yield | 1.98% | – |
| Revenue growth (YoY, latest qtr) | +3.1% | – |
| Net profit growth (YoY) | +641.1% | -27.5% |
| Gross margin | 29.4% | – |
| Operating margin | 10.3% | – |
| Net margin | 3.1% | – |
| Return on equity | 6.7% | -44.8% |
| Analyst target vs. price | +19.6% | +142.4% |
| Analyst buy share | 78% | 92% |
| RSI (14) | 62 | 51 |
| 30-day volatility | 38.6% | 80.1% |
| Max drawdown, 1 year | -25.6% | -38.1% |
| Trend read | Strong uptrend | Leaning bullish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- PRMB is the largest of the group by market value.
- PRAX has returned the most over the past year.
- PRMB has been the calmest stock over the last 30 days.